Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study

Acta Oncol. 2022 Mar;61(3):328-332. doi: 10.1080/0284186X.2021.2023215. Epub 2022 Jan 4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Androstenes* / therapeutic use
  • Castration
  • Drug Utilization
  • Humans
  • Male
  • Prostatic Neoplasms* / drug therapy

Substances

  • Androstenes
  • abiraterone